Geneos Wealth Management Inc. Lowers Stock Position in Pfizer Inc. (NYSE:PFE)

Geneos Wealth Management Inc. lessened its holdings in Pfizer Inc. (NYSE:PFEGet Rating) by 10.2% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 105,016 shares of the biopharmaceutical company’s stock after selling 11,917 shares during the period. Geneos Wealth Management Inc.’s holdings in Pfizer were worth $5,436,000 at the end of the most recent quarter.

Several other hedge funds have also recently modified their holdings of PFE. Harvest Volatility Management LLC purchased a new stake in Pfizer during the first quarter valued at approximately $242,000. Power Corp of Canada purchased a new stake in Pfizer during the first quarter valued at approximately $1,216,000. Journey Strategic Wealth LLC lifted its position in Pfizer by 3.4% during the first quarter. Journey Strategic Wealth LLC now owns 19,711 shares of the biopharmaceutical company’s stock valued at $1,020,000 after acquiring an additional 654 shares during the last quarter. Goff John C purchased a new stake in Pfizer during the first quarter valued at approximately $273,000. Finally, Wafra Inc. lifted its position in Pfizer by 0.8% during the first quarter. Wafra Inc. now owns 1,326,030 shares of the biopharmaceutical company’s stock valued at $68,649,000 after acquiring an additional 10,410 shares during the last quarter. Hedge funds and other institutional investors own 67.90% of the company’s stock.

Analysts Set New Price Targets

PFE has been the subject of a number of analyst reports. SVB Leerink decreased their target price on shares of Pfizer from $55.00 to $53.00 and set a “market perform” rating for the company in a research report on Friday, July 29th. JPMorgan Chase & Co. set a $57.00 price target on shares of Pfizer in a report on Tuesday, June 28th. Barclays set a $50.00 price target on shares of Pfizer in a report on Thursday, September 1st. UBS Group set a $59.00 price target on shares of Pfizer in a report on Thursday, September 1st. Finally, Morgan Stanley decreased their price target on shares of Pfizer from $52.00 to $49.00 and set an “equal weight” rating for the company in a report on Friday, July 8th. Nine analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Pfizer presently has a consensus rating of “Moderate Buy” and a consensus target price of $57.33.

Pfizer Stock Down 0.2 %

PFE stock opened at $47.76 on Tuesday. The firm has a market cap of $268.05 billion, a PE ratio of 9.35, a P/E/G ratio of 0.59 and a beta of 0.70. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.20 and a current ratio of 1.42. The firm’s fifty day moving average is $49.61 and its 200 day moving average is $50.49. Pfizer Inc. has a one year low of $40.94 and a one year high of $61.71.

Pfizer (NYSE:PFEGet Rating) last released its quarterly earnings results on Thursday, July 28th. The biopharmaceutical company reported $2.04 EPS for the quarter, beating the consensus estimate of $1.95 by $0.09. The company had revenue of $27.74 billion for the quarter, compared to analyst estimates of $26.20 billion. Pfizer had a net margin of 28.92% and a return on equity of 43.18%. The firm’s revenue was up 46.8% on a year-over-year basis. During the same quarter last year, the business earned $1.07 earnings per share. On average, research analysts forecast that Pfizer Inc. will post 6.54 EPS for the current year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 6th. Stockholders of record on Wednesday, June 29th were given a $0.40 dividend. The ex-dividend date was Thursday, July 28th. This represents a $1.60 annualized dividend and a dividend yield of 3.35%. Pfizer’s dividend payout ratio (DPR) is 31.31%.

About Pfizer

(Get Rating)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.

Featured Stories

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFEGet Rating).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.